Earnings Call · Q3 FY2022·2022-11-14

Q3 22EPS +7.14%·Rev n/aQ2 22EPS +28.57%·Rev n/aQ1 22EPS -45.45%·Rev n/aQ4 21EPS +8.33%·Rev n/a⚠ consensus missing

PDS Biotechnology Corp PDSB

Gabrielle DeGravina — Unknown

Frank Bedu-Addo — Chief Executive Officer

Lauren Wood — Chief Medical Officer

Matt Hill — Chief Financial Officer

+26.1%1d on move date+26.9% vs SPY3d+51.4%5d+54.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PDSB calls or request research access.

More PDSB calls Browse calls Request research access